Tirzepatide
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.
Comprehensive Dosing Guide
What is Tirzepatide?
Tirzepatide is a medication used to help manage type 2 diabetes and support weight loss in adults who are overweight or have obesity along with other health issues like high blood pressure or high cholesterol.
It works as a dual GIP/GLP-1 receptor agonist, meaning it activates two different hormone pathways that help control blood sugar and reduce appetite more effectively than single-pathway medications.
Quick Dosing Reference
Frequency
Once Weekly
Same day each week
Timing
Any Time of Day
With or without food
Dose Range
2.5 - 15mg
Gradual escalation over weeks
When is Tirzepatide Used?
Type 2 Diabetes
- Helps control blood sugar levels
- Can be used alone or with other diabetes medications
- Maintenance dose typically 5-15mg weekly
Weight Loss
- For BMI of 30+ (obesity)
- For BMI 27+ with weight-related conditions
- Target dose is 15mg weekly for maximum effect
What Results to Expect
Week 4-8
2-4%
Initial weight loss
Week 12-16
5-10%
Significant progress
Week 72
15-22%
Peak results (trials)
Medical Disclaimer
Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.